Primary non-Hodgkin’s lymphoma of liver with humoral hypercalcaemia

Cheruppolil R. Santhosh-Kumar,1 Dahish S.S. Ajarim1 and Frederick D. Shipkey2*

Departments of 1Medicine and 2Pathology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.

Summary: A case of primary non-Hodgkin’s lymphoma of the liver with associated humoral hypercalcaemia is described. The patient was successfully treated with combination chemotherapy. A similar association has not been reported previously.

Introduction

Involvement of the liver in lymphoma commonly occurs in later stages of the disease.1,2 Non-Hodgkin’s lymphoma originating in the liver is rare. A diagnosis of primary non-Hodgkin’s lymphoma of the liver (PNHLL) is seldom considered, especially in areas with high prevalence for primary hepatocellular carcinoma.3

Hypercalcaemia is an infrequent complication of non-Hodgkin’s lymphoma occurring in less than 2% of cases.4 The hypercalcaemia in such cases is usually attributed to bone involvement. We report a patient with PNHLL and hypercalcaemia without evidence of bone metastasis. A similar association has not been previously reported. Previous cases of PNHLL are reviewed and possible mechanisms of hypercalcaemia are discussed.

Case report

A 37 year old Yemeni male was referred for further investigation of possible liver metastasis from an unknown primary tumour. The patient gave a history of right upper abdominal swelling and pain for 4 months and progressive non-obstructive jaundice and vomiting for 2 months. He had lost 20 kg in weight and had night sweats without fever. There was no past history of jaundice or alcohol intake. Physical examination showed a cachectic, jaundiced man with no peripheral lymphadenopathy or stigmata of chronic liver disease. A tender diffusely enlarged liver was palpable to 5 cm below the right costal margin with a span of 20 cm. There was no splenomegaly. Systemic examination was otherwise normal.

Laboratory analysis showed persistent hypercalcaemia (range 3.25 to 3.92 mmol/l, corrected for albumin), with normal serum phosphate and low chloride (range 94–99 mmol/l). Blood urea and creatinine were normal. Serum immunoreactive parathyroid hormone (PTH) was 9 pmol/l (normal 44–68) (radioimmunoassay sensitive to mid-region of parathyroid hormone, Bioscientia Laboratories, Mainz, West Germany), with serum calcium in normal range and 1-alpha, 25-dihydroxy vitamin D3 was normal at 31 μg/l (normal 20–100). Serum bilirubin was 71 μmol/l, alanine transaminase 77 U/l, aspartate transaminase 94 U/l, gamma GT 431 U/l, alkaline phosphatase 1518 U/l and lactate dehydrogenase 1032 U/l. Total serum protein was 71 g/l with albumin of 28.8 g. Serum immunoelectrophoresis showed polyclonal increase in gamma globulins. Haemogram was normal. Serum ferritin was elevated at 537 μg/ml. Prothrombin time was normal. Hepatitis B (HB) surface antigen was negative but anti-Hbc and anti-Hbs were weakly reactive. Antibodies to human T cell leukaemia virus (HTLV-III) were absent in serum.

Computed tomographic (CT) scans (Figure 1) of the abdomen performed a week prior to admission showed multiple, discrete, rounded lesions in both lobes of the liver. There was no evidence of splenomegaly or lymph node enlargement. Chest X-ray, barium enema and upper gastrointestinal endoscopy were normal. Bone marrow aspirates and biopsies from both iliac crests did not show any abnormality. Skeletal radiology showed generalized decrease in bone density with no focal lesions.99mTc isotope bone scan showed generalized increased uptake without any focal lesions.

Correspondence: C.R. Santhosh-Kumar, M.R.C.P. Division of Medical Oncology, University of Colorado Cancer Center, Denver, Colorado 80262, USA.
*Present address: Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Accepted: 29 January 1990
Liver biopsy showed complete replacement by large lymphoid cells with cleaved nuclei, prominent central nucleoli and numerous mitotic figures (Figure 2). Stains for HBsAg, alpha fetoprotein and epithelial membrane antigen were negative. A diagnosis of primary diffuse large cell non-Hodgkin’s lymphoma was limited to the liver was established.

Chemotherapy was instituted with a combination of methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (MACOP-B). Serum calcium returned to normal on the fourth day of chemotherapy and remained normal at the time of last assessment.

Ultrasound and CT scans of the abdomen on completion of MACOP-B treatment, at 15 weeks, showed substantial resolution of the liver lesions except for two areas of low attenuation. Ultrasound guided liver biopsy of the areas did not show any evidence of lymphoma. Subsequently he was given two cycles of chemotherapy with ifosfamide and etoposide over a period of 6 weeks. CT scans of the liver continued to show two small lesions and a repeat liver biopsy did not show any evidence of lymphoma. No further treatment was given. A repeat isotope bone scan was normal. The patient remains in continuing complete remission at last assessment, 24 months after diagnosis.

Discussion

The diagnosis of PNHLL in our patient is based on histological diagnosis of lymphoma in liver with primary symptoms of liver disease, absence of lymphadenopathy, splenomegaly or other organ involvement and normal bone marrow examination and blood counts. The hypercalcaemia in our patient was related to the lymphoma since there was no history of vitamin or mineral intake, prolonged immobilization, signs of renal, bone or endocrine disease or sarcoidosis. We believe that the pathogenesis of hypercalcaemia is humoral as skeletal radiology and isotope scans showed a picture of generalized bone resorption without focal metastatic deposits. Associated primary hyperparathyroidism as a cause of osteoclastic bone resorption was excluded because of reduced PTH and vitamin D3 levels.

Primary hepatic lymphoma has been reported in 31 patients, of which 8 were autopsy diagnoses. Twenty one patients were males. Clinical presentation was generally non-specific with abdominal pain and weight loss being the predominant symptoms. The liver lesions were in the form of single nodules in 15 patients and multiple in 16. The lymphomas were of diffuse large cell type in the majority of cases. Of the 23 patients diagnosed in life, 7 were treated with surgery and or chemotherapy and 12 with chemotherapy alone. The median survival of these patients was 1.8 years with a range of 0 to 10 years.

Hypercalcaemia was not associated with any of the previously reported cases of PNHLL. Hypercalcaemia has been described in non-Hodgkin’s lymphoma and Hodgkin’s disease rarely in the absence of bone involvement, where humoral mediators like vitamin D3 and PTH-like substances have been implicated. Other agents like epidermal growth factor, platelet derived growth factor, tumour necrosis factor, osteoclast activating factor and prostaglandins have been suggested as humoral mediators of hypercalcaemia in the past.

Recently, several investigators have isolated a PTH-like protein thought to be responsible for humoral hypercalcaemia of malignancy, mainly in patients with solid tumours. This protein has structural and functional similarities to human PTH and recently a radioimmunoassay has been developed for quantitative analysis.

In summary we report the first case of PNHLL associated with humoral hypercalcaemia of malignancy which was successfully treated with
chemotherapy. A diagnosis of lymphoma should be considered while investigating a patient with suspected liver metastasis as this may be a potentially curable condition.

Acknowledgements
We thank Professor B. Ayoola, Gastroenterology Division, for review of the manuscript and Mr K.C. Kyriacou for help with photography.

References
Primary non-Hodgkin's lymphoma of liver with humoral hypercalcaemia.
C. R. Santhosh-Kumar, D. S. Ajarim and F. D. Shipkey

doi: 10.1136/pgmj.66.778.679

Updated information and services can be found at:
http://pmj.bmj.com/content/66/778/679

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/